Newsbenzinga
ArriVent Says Phase 3 Trial Of Firmonertinib In EGFR Exon 20 Lung Cancer Missed Primary Progression-Free Survival Endpoint
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…